ID
45756
Descripción
Principal Investigator: Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Endometrial Neoplasms,Carcinoma, Endometrioid https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001153 The purpose of this study was to identify somatic (tumor-specific) mutations in advanced stage endometrioid endometrial carcinoma tumor exomes. The dataset was generated at the NIH Intramural Sequencing Center (NISC) and NHGRI by next generation sequencing the exomes of 19 de-identified primary tumor DNAs, from advanced stage tumors, and matched non-tumor DNAs.
Link
Palabras clave
Versiones (1)
- 5/6/23 5/6/23 - Chiara Middel
Titular de derechos de autor
Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Subido en
5 de junio de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001153 Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma
Subject ID and gender of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Sample ID, subject ID, and sample use variable obtained from participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Subject ID and gender of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Sample ID, analyte type, body site where sample was obtained, histological type of sample, tumor status of sample, primary tumor location, primary or metastatic tumor, and sequencing center of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
Similar models
Subject ID and gender of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Sample ID, subject ID, and sample use variable obtained from participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Subject ID and gender of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Sample ID, analyte type, body site where sample was obtained, histological type of sample, tumor status of sample, primary tumor location, primary or metastatic tumor, and sequencing center of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
Sin comentarios